Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2022 Jul 15;25(4):804. doi: 10.1038/s41391-022-00578-7

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Scott T Tagawa 1, Krishnan Ramaswamy 2,, Ahong Huang 3, Jack Mardekian 2, Neil M Schultz 4, Li Wang 3, Rickard Sandin 5, Stanislav Lechpammer 6, Daniel J George 7
PMCID: PMC9705240  PMID: 35840724

Correction to: Prostate Cancer and Prostatic Diseases 10.1038/s41391-021-00318-3, published online 21 February 2021

In the sentence beginning ‘After adjusting for age...’ in this article, the value of upper CI limit ‘0.84’ should have read ‘0.94’.

In the sentence beginning ‘Unlike the overall population...’ in this article, the value ‘n = 700’ should have read ‘n = 786’.

In the sentence beginning ‘Nearly half (46,5%)...’ in this article, the value ‘46,5%’ should have read ‘49,5%’.

In Table 2 in the Supplementary PDF for this article, the line ‘Abiraterone followed by chemotherapy (c) 74 (3.80)’ has been deleted.

The original article has been corrected.


Articles from Prostate Cancer and Prostatic Diseases are provided here courtesy of Nature Publishing Group

RESOURCES